BIAL is presenting 11 research posters at the 19th International Congress of Parkinson’s Disease and Movement Disorders (June 14-15, San Diego, Calif.). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations.

Results from BIPARK-I confirming that opicapone is effective at reducing OFF-time with a favorable profile compared to entacapone, and is associated with significant improvements in both patient and clinician global impressions of change, in contrast to entacapone, which showed no significant differences compared to placebo in either assessment. 

READ FULL ARTICLE Curated publisher From News Medical